BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:21 PM
 | 
Mar 31, 2008
 |  BC Extra  |  Company News

Takeda, Cell Genesys in GVAX deal

Cell Genesys (NASDAQ:CEGE) granted Takeda (Tokyo:4502) exclusive, worldwide rights to commercialize GVAX vaccine for prostate cancer. The allogeneic cancer vaccine engineered to secrete granulocyte...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >